Bellicum Pharmaceuticals マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Dave Maggio

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2.2yrs
取締役会の平均在任期間	5yrs

経営陣の近況

Recent updates

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Aug 11

Bellicum launches $25M underwritten offering

Oct 29

CEO（最高経営責任者

Dave Maggio (63 yo)

less than a year

在職期間

Mr. David M. Maggio, also known as Dave, serves as Chief Executive Officer of Bellicum Pharmaceuticals, Inc. since February 2, 2024. Mr. Maggio has broad domestic and global experience in executing financi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Maggio	Chief Executive Officer	less than a year	データなし	データなし
Joseph Senesac	Senior Vice President of Technical Operations & Quality	2.2yrs	データなし	データなし
Alan Smith	Chief Scientific Officer	3.8yrs	US$791.68k	データなし

2.2yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: BLCMの経営陣は経験豊富であると考えられます ( 2.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Fair	Director	less than a year	US$1.39m	0.11% $ 972.6
Daniel Powell	Member of Scientific & Clinical Advisory Board	5yrs	データなし	データなし
Marco Davila	Member of Scientific & Clinical Advisory Board	5yrs	データなし	データなし
Charles Sentman	Member of Scientific & Clinical Advisory Board	5yrs	データなし	データなし
Gianpietro Dotti	Member of Scientific & Clinical Advisory Board	5yrs	データなし	データなし
Malcom Brenner	Member of Scientific & Clinical Advisory Board	5yrs	データなし	データなし
Christopher Klebanoff	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし

5.0yrs

平均在職期間

経験豊富なボード: BLCMの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

Bellicum Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Consensus EPS estimates fall by 39%

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Price target decreased to US$5.00

Insufficient new directors

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$5.00

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: US$4.65

Price target lowered to US$4.50

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum launches $25M underwritten offering

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - US$6.28

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

マネジメント基準チェック /24